beat · 32 stories
Rheumatoid arthritis has had one goal for decades: remission, judged by a score that mixes lab markers, joint counts and how the patient feels.
The French drugmaker Servier paid $1.55 billion cash for sevasemten. It failed to slow Becker muscular dystrophy, a rare genetic condition with no approved treatment.
A 2026 review of the third straight fall in U.S. overdose deaths names a changed drug supply, changed drug use and wider addiction treatment as candidate causes, and flags Medicaid cuts as a risk to treatment.
TRAM-AI (Transparency Reporting of Medical Imaging Datasets for AI) gives medical imaging AI a 14-item audit; on 10 pilot datasets, basic de-identification hit 90%, long-term archive validation just 10%.
A palladium-coated hollow-fiber membrane captured six 'forever chemicals' (PFAS) and cleaved the carbon–fluorine bond that makes them persist, in one ambient step; ~10% metal loss over 58 days sets the cost ceiling.
Order 818 is a Chinese rule adding a parallel review track for experimental cell, gene, and regenerative therapies, with a wider front door and a hard safety wall at the end.
A 32-patient postmortem study compared a leading Alzheimer's blood test with brain tissue from the same donors. The blood marker, a tau fragment called pTau217, tracked 0.73–0.78 against the cortex.
The workplan schedules finalization of the January 2025 AI lifecycle draft and the change-control framework that lets adaptive medical models update after approval. Comments close 30 November.
The $1 billion Cambridge building opens with 10 floors of interconnecting labs and a 1,100-employee launch roster, slotting next to AZ's existing 100 Binney genomic-medicine footprint.
The FDA is soliciting public comment on cardiac monitoring, dosing limits, and trial-stopping rules for the first federal ibogaine research program, a $50M initiative born from an April executive order.
In-Q-Tel, the BioNTech co-founder's family office, and the Slovak government are betting on a startup that wants to replace 40-year-old mRNA chemistry with engineered cells.
A University of Sydney team built a gene-expression benchmark for lab-grown embryo models, finding each of the four leading methods captures part of real human development but none yet match it fully.